Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Shares Outstanding: 2010-2024

Historic Shares Outstanding for Altimmune (ALT) over the last 15 years, with Dec 2024 value amounting to $72.4 million.

  • Altimmune's Shares Outstanding rose 34.41% to $95.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $95.6 million, marking a year-over-year increase of 34.41%. This contributed to the annual value of $72.4 million for FY2024, which is 2.37% up from last year.
  • Per Altimmune's latest filing, its Shares Outstanding stood at $72.4 million for FY2024, which was up 2.37% from $70.7 million recorded in FY2023.
  • In the past 5 years, Altimmune's Shares Outstanding ranged from a high of $72.4 million in FY2024 and a low of $37.1 million during FY2020.
  • Moreover, its 3-year median value for Shares Outstanding was $70.7 million (2023), whereas its average is $64.1 million.
  • Data for Altimmune's Shares Outstanding shows a peak YoY spiked of 142.57% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Altimmune's Shares Outstanding stood at $37.1 million in 2020, then increased by 10.37% to $41.0 million in 2021, then increased by 20.02% to $49.2 million in 2022, then spiked by 43.65% to $70.7 million in 2023, then rose by 2.37% to $72.4 million in 2024.